NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Helfand M. Screening for Thyroid Disease [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2004 Jan. (Systematic Evidence Reviews, No. 23.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Screening for Thyroid Disease

Screening for Thyroid Disease [Internet].

Show details

References

1.
Hollowell J G, Staehling N W, Flanders W D. et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III) J Clin Endocrinol Metab. 2002;87:489–499. [PubMed: 11836274]
2.
Canaris G J, Manowitz N R, Mayor G, Ridgway E C. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160:526–534. [PubMed: 10695693]
3.
Kanaya A M, Harris F, Volpato S, Perez-Stable E J, Harris T, Bauer D C. Association between thyroid dysfunction and total cholesterol level in an older biracial population: the health, aging and body composition study. Arch Intern Med. 2002;162:773–779. [PubMed: 11926850]
4.
Eddy D. How to think about screening. In: Eddy D, editor. Common Screening Tests. Philadelphia: American Coll Physicians; 1991; 1–21.
5.
Billewicz W Z, Chapman R S, Crooks J, Day M E, Gossage J, Wayne E. et al. Statistical methods applied to the diagnosis of hypothyroidism. Q J Med. 1969;38:255–266. [PubMed: 4181088]
6.
Crooks J, Murray I, Wayne E J. Statistical methods applied to the clinical diagnosis of thyrotoxicosis. Q J Med. 1959;28:211–234. [PubMed: 13658351]
7.
Eden S, Sundbeck G, Lindstedt G. et al. Screening for thyroid disease in the elderly. Serum concentrations of thyrotropin and 3,5,3'-triiodothyronine in a representative population of 79-year-old women and men. Comp Gerontol. 1988;2:40–45. [PubMed: 3197053]
8.
Helfand M, editor. Screening for thyroid dysfunction: Rationale, strategies, and cost-effectiveness. St. Louis: Mosby-Year Book, Inc.; 1992.
9.
O'Reilly D S. Thyroid function tests-time for a reassessment. BMJ. 2000;320:1332–1334. [PMC free article: PMC1127319] [PubMed: 10807634]
10.
Danese M D, Powe N R, Sawin C T, Ladenson P W. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. JAMA. 1996;276:285–292. [PubMed: 8656540]
11.
Ladenson P W, Singer P A, Ain K B. et al. American Thyroid Association guidelines for detection of thyroid dysfunction. [erratum appears in Arch Intern Med 2001 Jan 22;161(2):284] Arch Intern Med. 2000;160:1573–1575. [PubMed: 10847249]
12.
McDermott M T, Ridgway E C. Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Metab. 2001;86:4585–4590. [PubMed: 11600507]
13.
Chu J W, Crapo L M. The treatment of subclinical hypothyroidism is seldom necessary. J Clin Endocrinol Metab. 2001;86:4591–4599. [PubMed: 11600508]
14.
Helfand M, Crapo LM. Testing for suspected thyroid disease. In: Sox HC, editor. Common Diagnostic Tests. Philadelphia: American College of Physicians; 1990.
15.
Jaeschke R, Guyatt G, Gerstein H. et al. Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med. 1996;11:744–749. [PubMed: 9016421]
16.
Parle J, Franklyn J, Cross K, Jones S, Sheppard M. Prevalence and follow-up of abnormal thyrotropin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf) 1991;34:77–83. [PubMed: 2004476]
17.
Sundbeck G, Jagenburg R, Johansson P-M, Eden S, Lindstedt G. Clinical significance of a low serum thyrotropin concentration by chemiluminometric assay in 85-year-old women and men. Arch Intern Med. 1991;151:549–556. [PubMed: 1900411]
18.
Sawin C T, Geller A, Kaplan M M, Bacharach P, Wilson P W F, Hershman J M. Low serum thyrotropin (Thyroid-Stimulating Hormone) in older persons without hyperthyroidism. Arch Intern Med. 1991;151:165–168. [PubMed: 1985591]
19.
Attia J, Margetts P, Guyatt G. Diagnosis of thyroid disease in hospitalized patients. A systematic review. Arch Intern Med. 1999;159:658–665. [PubMed: 10218744]
20.
Sundbeck G, Lundberg P A, Lindstedt G, Svanborg A, Eden S. Screening for thyroid disease in the elderly. Serum free thyroxine and thyrotropin concentrations in a representative population of 81-year-old women and men. Aging (Milano) 1991;3:31–37. [PubMed: 2065125]
21.
Drinka P J, Amberson J, Voeks S K, Schomisch J, Schirz P, Christensen D. Low TSH levels in nursing home residents not taking thyroid hormone. J Am Geriatr Soc. 1996;44:573–577. [PubMed: 8617908]
22.
Bondeson E, Meisel T, Eggertsen R. [A simple health control for the elderly. Screening for vitamin B12 deficiency and thyroid disease]. [Swedish] Lakartidningen. 1997;94:4329–4332. [PubMed: 9424529]
23.
Wang C, Crapo L M. The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am. 1997;26:189–218. [PubMed: 9074859]
24.
Helfand M, Crapo L M. Screening for thyroid disease. Ann Intern Med. 1990;112:840–849. [PubMed: 2111649]
25.
Helfand M, Redfern C C. Clinical guideline, part 2. Screening for thyroid disease: an update. American College of Physicians [published erratum appears in Ann Intern Med 1999 Feb 2;130(3):246] Ann Intern Med. 1998;129:144–158. [PubMed: 9669977]
26.
Kung A W, Janus E D. Thyroid dysfunction in ambulatory elderly Chinese subjects in an area of borderline iodine intake. Thyroid. 1996;6:111–114. [PubMed: 8733881]
27.
Danese D. Subclinical hypothyroidism in flight personnel: evaluation for suitability to fly. Int Rev Armed Forces Med Serv. 1997;70:32–36. [PubMed: 11540646]
28.
Fardella C, Poggi H, Gloger S, Rojas A, Velasquez C G, Barroileth S. et al. [High prevalence of subclinical thyroidal disease among individuals attended in health control]. [Spanish] Rev Med Chil. 2001;129:155–160. [PubMed: 11351466]
29.
Chuang C C, Wang S T, Wang P W, Yu M L. Prevalence study of thyroid dysfunction in the elderly of Taiwan. Gerontol. 1998;44:162–167. [PubMed: 9592689]
30.
Knudsen N, Jorgensen T, Rasmussen S, Christiansen E, Perrild H. The prevalence of thyroid dysfunction in a population with borderline iodine deficiency. Clin Endocrinol. 1999;51:361–367. [PubMed: 10469017]
31.
Lindeman R D, Schade D S, LaRue A. et al. Subclinical hypothyroidism in a biethnic, urban community. J Am Geriatr Soc. 1999;47:703–709. [PubMed: 10366170]
32.
Rivolta G, Cerutti R, Colombo R, Miano G, Dionisio P, Grossi E. Prevalence of subclinical hypothyroidism in a population living in the Milan metropolitan area. J Endocrinol Invest. 1999;22:693–697. [PubMed: 10595833]
33.
Hak A E, Pols H A, Visser T J, Drexhage H A, Hofman A, Witteman J C. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132:270–278. [PubMed: 10681281]
34.
Tunbridge W M G, Evered D C, Hall R. et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977;7:481–493. [PubMed: 598014]
35.
Sawin C, Geller A, Wolf P. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249–1252. [PubMed: 7935681]
36.
Vanderpump M P, Tunbridge W M G, French J M. et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol (Oxf) 1995;43:55–68. [PubMed: 7641412]
37.
HTDS Management Team. Hanford thyroid disease study final report. Seattle, WA: Fred Hutchinson Cancer Research Center; 2002.
38.
Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J. 2001;142:838–842. [PubMed: 11685172]
39.
Benjamin E J, Wolf P A, D'Agostino R B, Silbershatz H, Kannel W B, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946–952. [PubMed: 9737513]
40.
Parle J V, Maisonneuve P, Sheppard M C, Boyle P, Franklyn J A. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet. 2001;358:861–865. [PubMed: 11567699]
41.
Bauer D C, Nevitt M C, Ettinger B, Stone K. Low thyrotropin levels are not associated with bone loss in older women: a prospective study. J Clin Endocrinol Metab. 1997;82:2931–2936. [PubMed: 9284722]
42.
Uzzan B, Campos J, Cucherat M, Nony P, Boissel J P, Perret G Y. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab. 1996;81:4278–4289. [PubMed: 8954028]
43.
Faber J, Galloe A M. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol. 1994;130:350–356. [PubMed: 8162163]
44.
Gurlek A, Gedik O. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid. 1999;9:539–543. [PubMed: 10411115]
45.
Mudde A H, Reijnders F J, Kruseman A C. Peripheral bone density in women with untreated multinodular goitre. Clin Endocrinol. 1992;37:35–39. [PubMed: 1424190]
46.
Foldes J, Tarjan G, Szathmari M, Varga F, Krasznai I, Horvath C. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis? Clin Endocrinol. 1993;39:521–527. [PubMed: 8252739]
47.
Kumeda Y, Inaba M, Tahara H. et al. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab. 2000;85:4157–4161. [PubMed: 11095447]
48.
Cummings S, Nevitt M C, Browner W S. et al. Risk factors for hip fracture in white women. N Engl J Med. 1995;332:767–773. [PubMed: 7862179]
49.
Bauer D C, Ettinger B, Nevitt M C, Stone K L. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med. 2001;134:561–568. [PubMed: 12803168]
50.
Sherman S I, Simons L, Ladenson P W. Clinical and socioeconomic predispositions to complicated thyrotoxicosis: a predictable and preventable syndrome? Am J Med. 1996;101:192–198. [PubMed: 8757360]
51.
Sundbeck G, Eden S, Jagenburg R, Lindstedt G. Thyroid dysfunction in 85-year-old men and women. Influence of non-thyroidal illness and drug treatment. Acta Endocrin. 1991;125:475–486. [PubMed: 1684684]
52.
Kalmijn S, Mehta K M, Pols H A, Hofman A, Drexhage H A, Breteler M M. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam Study. Clin Endocrinol. 2000;53:733–737. [PubMed: 11155096]
53.
Biondi B, Palmieri E A, Fazio S. et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab. 2000;85:4701–4705. [PubMed: 11134131]
54.
Biondi B, Fazio S, Palmieri E A. et al. [Effects of chronic subclinical hyperthyroidism from levothyroxine on cardiac morphology and function]. [Italian] Cardiologia. 1999;44:443–449. [PubMed: 10389349]
55.
Schlote B, Nowotny B, Schaaf L. et al. Subclinical hyperthyroidism: physical and mental state of patients. Eur Arch Psychiatry Clin Neurosci. 1992;241:357–364. [PubMed: 1504113]
56.
Figge J, Leinung M, Goodman A D. et al. The clinical evaluation of patients with subclinical hyperthyroidism and free triiodothyronine (free T3) toxicosis. Am J Med. 1994;96:229–234. [PubMed: 8154510]
57.
Rieu M, Bekka S, Sambor B, Berrod J L, Fombeur J P. Prevalence of subclinical hyperthyroidism and relationship between thyroid hormonal status and thyroid ultrasonographic parameters in patients with non-toxic nodular goitre. Clin Endocrinol. 1993;39:67–71. [PubMed: 8348708]
58.
Biondi B, Fazio S, Cuocolo A. et al. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1996;81:4224–4228. [PubMed: 8954019]
59.
Mason R L, Hunt H M, Hurxthal L. Blood cholesterol values in hyperthyroidism and hypothyroidism. N Engl J Med. 1930;203:1273–1278.
60.
Johnston J, McLelland A, O'Reilly D S. The relationship between serum cholesterol and serum thyroid hormones in male patients with suspected hypothyroidism. Ann Clin Biochem. 1993;30:256–9. [PubMed: 8517607]
61.
Valdemarsson S, Hansson P, Hedner P, Nilsson-Ehle P. Relations between thyroid function, hepatic and lipoprotein lipase activities, and plasma lipoprotein concentrations. Acta Endocrinol. 1983;104:50–56. [PubMed: 6624364]
62.
Elder J, McLelland A, O'Reilly D S, Packard C J, Series J J, Shepherd J. The relationship between serum cholesterol and serum thyrotropin, thyroxine, and tri-iodothyronine concentrations in suspected hypothyroidism. Ann Clin Biochem. 1990;27:110–113. [PubMed: 2327707]
63.
Bindels A J, Westendorp R G, Frolich M, Seidell J C, Blokstra A, Smelt A H. The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: a need for case-finding? Clin Endocrinol. 1999;50:217–220. [PubMed: 10396365]
64.
Bauer D C, Ettinger B, Browner W S. Thyroid functions and serum lipids in older women: a population-based study. Am J Med. 1998;104:546–551. [PubMed: 9674717]
65.
Vanderpump M P, Tunbridge W M, French J M, Appleton D, Bates D, Clark F. et al. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. Thyroid. 1996;6:155–160. [PubMed: 8837320]
66.
Nedrebo B G, Ericsson U B, Nygard O. et al. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism. 1998;47:89–93. [PubMed: 9440483]
67.
Morris M S, Bostom A G, Jacques P F, Selhub J, Rosenberg I H. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. Atherosclerosis. 2001;155:195–200. [PubMed: 11223442]
68.
Diekman M J, van der Put N M, Blom H J, Tijssen J G, Wiersinga W M. Determinants of changes in plasma homocysteine in hyperthyroidism and hypothyroidism. Clin Endocrinol. 2001;54:197–204. [PubMed: 11207634]
69.
Lien E A, Nedrebo B G, Varhaug J E, Nygard O, Aakvaag A, Ueland P M. Plasma total homocysteine levels during short-term iatrogenic hypothyroidism. J Clin Endocrinol Metab. 2000;85:1049–1053. [PubMed: 10720038]
70.
Catargi B, Parrot-Roulaud F, Cochet C, Ducassou D, Roger P, Tabarin A. Homocysteine, hypothyroidism, and effect of thyroid hormone replacement. Thyroid. 1999;9:1163–1166. [PubMed: 10646653]
71.
Hussein W I, Green R, Jacobsen D W, Faiman C. Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism. Ann Intern Med. 1999;131:348–351. [PubMed: 10475887]
72.
Bicikova M, Tallova J, Hill M, Vanuga A, Putz Z, Tomandl J. Effect of treatment of hypothyroidism on the plasma concentrations of neuroactive steroids and homocysteine. Clin Chem Lab Med. 2001;39:753–757. [PubMed: 11592446]
73.
Barbe F, Klein M, Chango A. et al. Homocysteine, folate, vitamin B12, and transcobalamins in patients undergoing successive hypo- and hyperthyroid states. J Clin Endocrinol Metab. 2001;86:1845–1846. [PubMed: 11297639]
74.
Nystrom E, Caidahl K, Fager G, Wikkelso C, Lundberg P A, Lindstedt G. A double-blind cross-over 12-month study of L-thyroxine treatment of women with ‘subclinical’ hypothyroidism. Clin Endocrinol. 1988;29:63–75. [PubMed: 3073880]
75.
Cooper D S, Halpern R, Wood L C, Levin A A, Ridgway E C. L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Ann Intern Med. 1984;101:18–24. [PubMed: 6428290]
76.
Cooper D S. Clinical practice. Subclinical hypothyroidism. N Engl J Med. 2001;345:260–265. [PubMed: 11474665]
77.
Fahrenfort J J, Wilterdink A M, van der Veen E A. Long-term residual complaints and psychosocial sequelae after remission of hyperthyroidism. Psychoneuroendocrinology. 2000;25:201–211. [PubMed: 10674283]
78.
Allan W C, Haddow J E, Palomaki G E. et al. Maternal thyroid deficiency and pregnancy complications: implications for population screening. J Med Screen. 2000;7:127–130. [PubMed: 11126160]
79.
Haddow J E, Palomaki G E, Allan W C. et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999;341:549–555. [PubMed: 10451459]
80.
Klein R Z, Sargent J D, Larsen P R, Waisbren S E, Haddow J E, Mitchell M L. Relation of severity of maternal hypothyroidism to cognitive development of offspring. J Med Screen. 2001;8:18–20. [PubMed: 11373843]
81.
U.S. Preventive Services Task Force. Screening for thyroid disease. Guide to Clinical Preventive Services. Baltimore, MD: Williams & Wilkins; 1996.
82.
Osman F, Gammage M D, Sheppard M C, Franklyn J A. Clinical review 142. Cardiac dysrhythmias and thyroid dysfunction: the hidden menace? J Clin Endocrinol Metab. 2002;87:963–967. [PubMed: 11889143]
83.
Klein I, Ojamaa K. Mechanisms of disease: thyroid hormones and the cardiovascular system. N Engl J Med. 2001;344:501–509. [PubMed: 11172193]
84.
Stockigt J R. Case finding and screening strategies for thyroid dysfunction. Clin Chim Acta. 2002;315:111–124. [PubMed: 11728414]
85.
Toft A D. Clinical practice. Subclinical hyperthyroidism. N Engl J Med. 2001;345:512–516. [PubMed: 11519506]
86.
Tunbridge W M, Vanderpump M P. Population screening for autoimmune thyroid disease. Endocrinol Metab Clin North Am. 2000;29:239–253. [PubMed: 10874527]
87.
Weetman A P. Hypothyroidism: screening and subclinical disease. BMJ. 1997;314:1175–1178. [PMC free article: PMC2126522] [PubMed: 9146393]
88.
Tanis B C, Westendorp G J, Smelt H M. Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies. Clin Endocrinol. 1996;44:643–649. [PubMed: 8759176]
89.
Harris R, Helfand M, Woolf S. Methods of the 3rd U.S. Preventive Services Task Force. AJPM. 1999;20(3S):21–35.
90.
Mudde A H, Houben A J, Nieuwenhuijzen Kruseman A C. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol. 1994;41:421–424. [PubMed: 7955452]
91.
Faber J, Jensen I W, Petersen L, Nygaard B, Hegedus L, Siersbaek-Nielsen K. Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol. 1998;48:285–290. [PubMed: 9578817]
92.
Gonzalez Vilchez F, Castillo L, Pi J, Ruiz E. [Cardiac manifestations of primary hypothyroidism. Determinant factors and treatment response]. [Spanish] Rev Esp Cardiol. 1998;51:893–900. [PubMed: 9859712]
93.
Smith R N, Taylor S A, Massey J C. Controlled clinical trial of combined triiodothyronine and thyroxine in the treatment of hypothyroidism. BMJ. 1970;4:145–148. [PMC free article: PMC1819870] [PubMed: 4097650]
94.
Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange A J Jr. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med. 1999;340:424–429. [PubMed: 9971866]
95.
Berg J A, Mayor G H. A study in normal human volunteers to compare the rate and extent of levothyroxine absorption from Synthroid and Levoxine. J Clin Pharmacol. 1993;33:1135–1140. [PubMed: 1487553]
96.
Zelmanovitz F, Genro S, Gross J L. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses. J Clin Endocrinol Metab. 1998;83:3881–3885. [PubMed: 9814462]
97.
Ross D S. Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study. Am J Med. 1993;95:385–388. [PubMed: 8213870]
98.
Monzani F, Di Bello V, Caraccio N. et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. J Clin Endocrinol Metab. 2001;86:1110–1115. [PubMed: 11238494]
99.
Michalopoulou G, Alevizaki M, Piperingos G. et al. High serum cholesterol levels in persons with ‘high-normal’ TSH levels: should one extend the definition of subclinical hypothyroidism? Eur J Endocrinol. 1998;138:141–145. [PubMed: 9506856]
100.
Meier C, Staub J J, Roth C B. et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study) J Clin Endocrinol Metab. 2001;86:4860–4866. [PubMed: 11600554]
101.
Pollock M A, Sturrock A, Marshall K. et al. Thyroxine treatment in patients with symptoms of hypothyroidism but thyroid function tests within the reference range: randomised double blind placebo controlled crossover trial. BMJ. 2001;323:891–895. [PMC free article: PMC58535] [PubMed: 11668132]
102.
Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled trial. J Clin Endocrinol Metab. 2002;87:1533–1538. [PubMed: 11932277]
103.
Kong W M, Sheikh M H, Lumb P J. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. Am J Med. 2002;112:348–354. [PubMed: 11904108]
104.
Danese M D, Ladenson P W, Meinert C L, Powe N R. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab. 2000;85:2993–3001. [PubMed: 10999775]
105.
Skinner G R B, Holmes D, Ahmad A, Davies A, Benitez J. Clinical response to thyroxine sodium in clinically hypothyroid but biochemically euthyroid patients. J Nutr Environ Med. 2000;10:115–124.
106.
Greenspan S L, Greenspan F S. The effect of thyroid hormone on skeletal integrity. Ann Intern Med. 1999;130:750–758. [PubMed: 10357695]
Bookshelf ID: NBK42816

Views

  • PubReader
  • Print View
  • Cite this Page

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...